Thermo Fisher Scientific Inc. (FRA:TN8)
Germany · Delayed Price · Currency is EUR 488.45
-4.95 (-1.00%)
At close: Jan 30, 2026
Thermo Fisher Scientific Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 44,556 | 42,879 | 42,857 | 44,915 | 39,211 | |
Revenue Growth (YoY) | 3.91% | 0.05% | -4.58% | 14.55% | 21.70% |
Cost of Revenue | 25,984 | 25,130 | 25,662 | 25,944 | 19,573 |
Gross Profit | 18,572 | 17,749 | 17,195 | 18,971 | 19,638 |
Selling, General & Admin | 7,073 | 8,595 | 8,381 | 8,940 | 7,857 |
Research & Development | 1,397 | 1,390 | 1,337 | 1,471 | 1,406 |
Amortization of Goodwill & Intangibles | 1,730 | - | - | - | - |
Other Operating Expenses | - | 30 | 1 | - | 3 |
Operating Expenses | 10,200 | 10,015 | 9,719 | 10,411 | 9,266 |
Operating Income | 8,372 | 7,734 | 7,476 | 8,560 | 10,372 |
Interest Expense | -1,419 | -1,390 | -1,375 | -726 | -536 |
Interest & Investment Income | 993 | 1,078 | 879 | 272 | 43 |
Earnings From Equity Investments | -41 | -42 | -59 | -172 | -4 |
Currency Exchange Gain (Loss) | - | -16 | -29 | 102 | 162 |
Other Non Operating Income (Expenses) | -4 | 5 | 5 | -35 | -161 |
EBT Excluding Unusual Items | 7,901 | 7,369 | 6,897 | 8,001 | 9,876 |
Merger & Restructuring Charges | - | -104 | -220 | -68 | -72 |
Gain (Loss) on Sale of Investments | - | 21 | -46 | -161 | 66 |
Asset Writedown | - | -252 | -219 | -46 | -122 |
Legal Settlements | - | - | -19 | - | - |
Other Unusual Items | -633 | -39 | -154 | -63 | -911 |
Pretax Income | 7,268 | 6,995 | 6,239 | 7,663 | 8,837 |
Income Tax Expense | 547 | 657 | 284 | 703 | 1,109 |
Earnings From Continuing Operations | 6,721 | 6,338 | 5,955 | 6,960 | 7,728 |
Net Income to Company | 6,721 | 6,338 | 5,955 | 6,960 | 7,728 |
Minority Interest in Earnings | -17 | -3 | 40 | -10 | -3 |
Net Income | 6,704 | 6,335 | 5,995 | 6,950 | 7,725 |
Net Income to Common | 6,704 | 6,335 | 5,995 | 6,950 | 7,725 |
Net Income Growth | 5.83% | 5.67% | -13.74% | -10.03% | 21.18% |
Shares Outstanding (Basic) | 377 | 382 | 386 | 392 | 394 |
Shares Outstanding (Diluted) | 378 | 383 | 388 | 394 | 397 |
Shares Change (YoY) | -1.31% | -1.29% | -1.52% | -0.76% | -0.50% |
EPS (Basic) | 17.78 | 16.58 | 15.53 | 17.73 | 19.61 |
EPS (Diluted) | 17.74 | 16.53 | 15.45 | 17.63 | 19.46 |
EPS Growth | 7.32% | 6.99% | -12.37% | -9.40% | 21.93% |
Free Cash Flow | 6,293 | 7,267 | 6,927 | 6,911 | 6,789 |
Free Cash Flow Per Share | 16.65 | 18.97 | 17.85 | 17.54 | 17.10 |
Dividend Per Share | 1.720 | 1.560 | 1.400 | 1.200 | 1.040 |
Dividend Growth | 10.26% | 11.43% | 16.67% | 15.38% | 18.18% |
Gross Margin | 41.68% | 41.39% | 40.12% | 42.24% | 50.08% |
Operating Margin | 18.79% | 18.04% | 17.44% | 19.06% | 26.45% |
Profit Margin | 15.05% | 14.77% | 13.99% | 15.47% | 19.70% |
Free Cash Flow Margin | 14.12% | 16.95% | 16.16% | 15.39% | 17.31% |
EBITDA | 11,152 | 10,842 | 10,882 | 11,941 | 12,964 |
EBITDA Margin | 25.03% | 25.29% | 25.39% | 26.59% | 33.06% |
D&A For EBITDA | 2,780 | 3,108 | 3,406 | 3,381 | 2,592 |
EBIT | 8,372 | 7,734 | 7,476 | 8,560 | 10,372 |
EBIT Margin | 18.79% | 18.04% | 17.44% | 19.06% | 26.45% |
Effective Tax Rate | 7.53% | 9.39% | 4.55% | 9.17% | 12.55% |
Revenue as Reported | - | 42,879 | 42,857 | 44,915 | 39,211 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.